Visen Pharmaceuticals

About:

Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.

Website: http://www.visenpharma.com/

Top Investors: OrbiMed, Ascendis Pharma, Cormorant Asset Management, HongShan, Sofinnova Investments

Description:

VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.

Total Funding Amount:

$190M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Shanghai, Shanghai, China

Founded Date:

2018-11-07

Contact Email:

info(AT)visenpharma.com

Founders:

DanDan Dong

Number of Employees:

101-250

Last Funding Date:

2021-01-08

IPO Status:

Private

Industries:

© 2025 bioDAO.ai